Conditional approval for Sunrise Technologies:
This article was originally published in Clinica
The FDA has given Sunrise Technologies conditional approval to treat both of a patient's eyes on the same day using its laser vision correction system during clinical studies. The company had originally received FDA approval to treat the second eye after a six-month rest period following the first treatment. The FDA has asked Sunrise to make a minor change to the study protocol. The move follows requests from surgeons and patients wanting to have immediate treatment for the second eye after receiving initial treatment.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.